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 Abstract 
In chapter fifteen, ‘Clinical and medical management of conditions 
caused by MDMA or “Ecstasy”’, Andrew Parrott provides an overview of 
the evolution of the MDMA market over the years, which has become 
increasingly more complex and multifaceted with the introduction of 
products containing very high doses of MDMA or substances passed as 
MDMA but actually containing a series of different products. A detailed 
analysis of incidences, dangers, and available treatments has been 
provided as well as a review of causes of death and prevention 
strategies. Andrew Parrott will also discuss the clinical presentation of 
toxicity and clinical management strategies for clinicians. 
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Clinical and Medical Management of Conditions Caused by MDMA or 
‘Ecstasy’ 
Andrew C. Parrott 
Introduction 
The United Nations Office on Drugs and Crime (2018) noted that the 
term ‘novel psychoactive substances’ (NPS) had first been used around 
ten years previously. It reflected the dramatic expansion in novel 
substances becoming available to illicit drug users. On average, one new 
drug was uncovered by the professional drug agencies every week 
(UNODC, 2018). The use of the Internet and the dark web allowed drug 
users to purchase these novel substances very easily and have them 
delivered to their homes by the normal postal delivery services 
(Corazza, Schifano, & Parrott, 2013). The illicit drug scene was changing 
rapidly, and this was generating many new problems for the 
professional drug agencies. Several international conferences on this 
NPS phenomenon have been organized in recent years. The first was in 
Budapest (2011), followed by Swansea (2013), Rome (2014), and then 
again in Budapest (2016). The fifth conference was held at the United 
Nations in Vienna (2017), confirming the international importance of 
this problem. The papers from these meetings have been published in a 
series of special issues of the journal Human Psychopharmacology 
(Corazza et al., 2013; Corazza, Parrott, & Demetrovics, 2017; Parrott & 
Corazza, 2013). 
The UNODC (2018) report noted that 3,4-
methylenedioxymethamphetamine (MDMA or Ecstasy) was perhaps the 
first of these novel substances, although it was now well established. 
The report noted that in recent years the Ecstasy/MDMA market had 
become increasingly complex and multifaceted; some of the illicit 
supplies demonstrated an ‘extremely high MDMA content’, while some 
illegal drug factories in Europe were producing supplies on an industrial 
scale [note: the increasing death rates from recreational MDMA in 
recent years are debated more fully later]. When MDMA was first used 
as a recreational drug in the 1980s and 1990s, it was often misperceived 
as a relatively safe drug, since most of its damaging psychobiological 
effects were not then known. However, in the past thirty years, 
numerous scientific studies have revealed that MDMA has a wide range 
of damaging effects on human wellbeing (Parrott, 2001, 2006, 2013a, 
2013b, 2015). The aim of this article is to summarize these acute and 
chronic dangers and recommend methods for their management and 
treatment. 
Broad Overview of the Adverse Effects of MDMA 
This section will briefly overview the main dangers from recreational 
MDMA. It should be noted that these problems will be described more 
fully in later sections, where full reference support will be provided. 
Hyperthermia is experienced by most dance clubbers on MDMA, with 
average body temperature increases of around +1.0oC. More severe 
overheating (body temperature +40ºC) requires rapid cooling by air fans 
or ice baths, since without urgent medical intervention, this 
hyperthermia can be fatal. MDMA also impairs fluid control, with 
excessive fluid intake and retention causing hyponatraemia, the dilution 
of sodium electrolytes. Mild hyponatraemia had been found in 25% of 
female and 3% of male dance clubbers. Treatment involves the rapid re-
establishment of normal sodium levels intravenously, since severe 
hyponatraemia can be fatal. Other acute abreactions to MDMA include 
cardiac distress, heart attack, brain haemorrhage, and liver damage, 
with severe cases requiring liver transplantation. Disseminated 
intravascular coagulation may result in uncontrollable bleeding from 
multiple orifices, when death may be rapid. Most acute medical 
emergencies are treated successfully, although around 60 MDMA 
deaths occur in Great Britain each year, and international death rates 
are increasing. 
The chronic or repeated use of MDMA causes a range of 
neuropsychobiological problems. The repetitive overstimulation of the 
body and brain causes cumulative bio-energetic stress, which impairs 
key biological functions and disrupts homeostasis. The serotonergic 
neurotransmitter system in the brain is chronically damaged, a 
phenomenon termed ‘serotonergic neurotoxicity’. The stress hormone 
cortisol is increased by an average of 400% in three-month hair samples 
of regular Ecstasy/MDMA users. Biochemical makers of oxidative stress 
are increased, and white blood cell counts reduced. Thermal control 
may be reduced in chronic users, with practical implications for the lives 
of military personnel. Physical activity in hot conditions may exacerbate 
hyperthermia, while cold immersion may lead to excessive overcooling 
or hypothermia. Sleep problems are noted by 70% of recreational 
Ecstasy/MDMA users, with sleep apnoea developing in a minority. 
MDMA can lead to heightened depression, and other psychiatric 
problems, including stress, anxiety, impulsivity, anger, and physical 
aggression. For clinical management, the optimal treatment is drug 
cessation. Empirical research has shown that quitting Ecstasy/MDMA 
can lead to improved mental health. In neurocognitive terms, the 
recreational use of MDMA leads to disorders of memory and reduced 
cognitive skills. Even simple occupational tasks like ‘office work’ can be 
impaired. These neurocognitive impairments endure for several years 
post-cessation and may well be permanent. Basic cognitive skills are 
however retained. Psychomotor problems and reduced steadiness can 
develop in adults. Psychomotor retardation occurs in babies born to 
mothers who took recreational MDMA during pregnancy. 
All recreational CNS stimulants can lead to dependency, although this is 
less characteristic of MDMA. This is because the cost-benefit ratio 
deteriorates naturally, with repeated MDMA usage leading to weaker 
mood gains and stronger adverse effects. Hence most users quit on 
their own, although heavy users and bingers may need professional 
assistance. Cognitive guidance and insight therapy can explain how the 
drug is damaging and why abstinence is important. Clinical management 
should focus on developing new life skills which do not involve drug 
taking, since former users have an increased risk of developing other 
drug dependencies. Prevention is by far the safest option, with young 
people needing clear information about its damaging effects. The best 
practical advice is to never take MDMA. 
Table 15.1 Overview of Acute Medical Abreactions to MDMA and Their 
Treatment 
[Note to author: Tables are better viewed when changing your 'MS 
Word settings' to 'Web view']. 
Acute 
Abreaction  
Incidence-
Occurrence 
Management-
Treatment  
References 
    
Moderate 
thermal stress 
and increased 
body 
temperature 
Most 
recreational 
users at 
dances or 
parties  
If feeling hot, 
stop dancing. 
Avoid 
overheating 
since it can 
contribute to 
cumulative 
drug damage.  
Freedman et al., 
2005. 
Parrott, 2002, 
2006. 
Morefield et al., 
2009. 
Parrott & 
Young, 2015. 
Severe 
overheating 
and 
hyperthermia 
Case studies 
and reports, 
potentially 
lethal if not 
treated 
rapidly 
Take to hospital 
immediately; 
rapid cooling, 
ice baths, 
intravenous 
dantrolene. 
Hall & Henry, 
2006. 
Patel, Belson, 
Longwater, 
Olson, & Miller, 
2005 
Greene, Wood, 
& Dargan, 2009 
Mild 
hyponatraemia 
(sodium 
electrolyte 
dilution in 
blood) 
25% of 
females and 
3% of males at 
dance clubs 
Do not drink 
any more 
fluids. Seek 
medical blood 
testing. Do not 
take MDMA 
again. 
Van Dijken et 
al., 2013. 
Baggott et al., 
2016 
Strong 
hyponatraemia 
(more severe 
sodium 
depletion in 
blood) 
Case reports 
and medical 
surveys, 
potentially 
lethal if not 
treated 
rapidly 
Seek urgent 
blood test, 
intravenous 
sodium 
immediately.  
Hall & Henry, 
2006. Rosenson 
et al., 2007. 
Halpern et al., 
2011 
Serotonin 
syndrome 
Mild 
syndrome 
usual for 
recreational 
users, strong 
syndrome in a 
minority  
Rest and 
recover. Do not 
take other 
serotonergic 
drugs. Do not 
take MDMA 
again. 
Parrott, 2002, 
2006. 
Chronic 
tolerance 
Dosage 
escalation 
very common, 
bingeing in 
experienced 
users, heavy 
users may 
inject 
Generally self-
limiting. Most 
users quit on 
their own as 
the cost-benefit 
ratio 
deteriorates. 
Topp, Hando, 
Dillon, Roche, & 
Solowij, 1999 
Fox, Parrott, & 
Turner, 2001 
Parrott, 2005, 
2010. 
Downey et al., 
2017 
Cardiac 
problems, liver 
failure, single 
and multi-
organ failure  
Severe 
abreactions 
rare or 
unusual, mild 
abreactions 
may be 
underreported  
Seek standard 
medical 
treatments, 
liver 
transplantation, 
blood platelets 
to reverse 
uncontrollable 
bleeding. 
Smith, Simpson, 
Garden, & 
Wigmore, 2005. 
Hall & Henry, 
2006 
Cortisol 
increase  
Group 
increase of 
800% in dance 
clubbers 
Stop dancing, 
and rest.  
Parrott, Lock, 
Conner, Kissling, 
& Thome, 2008 
Parrott, 2009, 
2016 
Death Around 
60/year in UK, 
international 
death rates 
may be 
increasing  
Do not take 
MDMA again. 
 
Chadwick, 
Curry, Linsley, 
Freemont, & 
Doran, 1991. 
Schifano et al., 
2010. 
Santacroce et 
al., 2017 
    
 
Neurotransmitter and Neurohormonal Effects of MDMA 
The chemical name for MDMA is 3,4-
methylenedioxymethamphetamine, which identifies it as a 
methamphetamine derivative. Indeed, MDMA displays many 
psychophysiological similarities to other recreational stimulant drugs, 
such as methamphetamine, amphetamine, and cocaine (McDowell & 
Kleber, 1994; Ricaurte, Yuan, & McCann, 2000; Parrott, 2008, 2015). Its 
effects on dopamine and noradrenaline lead to stimulatory effects, such 
as greater alertness and more intense moods. Hence in laboratory 
studies, acute MDMA leads to increased heart rate, faster breathing, 
and heightened blood pressure (Liechti, Gamma, & Vollenweider, 2001). 
At dance clubs and raves, the stimulatory effects can be much stronger 
because of the interactive effects of taking a stimulant drug in hot and 
overcrowded conditions—while dancing vigorously (Parrott, 2002, 
2004). Many recreational users feel highly aroused, with one person 
stating that he or she felt as if there were a ‘stereo inside my body’ 
(Cohen, 1998; Parrott, 2010). 
Unlike the more traditional CNS amphetamines, MDMA displays a 
strong affinity for the serotonin transporter (SERT). Hence an acute does 
of MDMA reverses normal serotonin reuptake and generates a large 
efflux of serotonin into the synaptic cleft (Berger, Gu, & Azmitia, 1992). 
This heightened stimulation is accompanied by elements of the 
serotonin syndrome, with ‘hyperactivity, mental confusion, 
hyperthermia, and trismus (jaw clenching), being typical on-drug 
experiences for most Ecstasy users’ (Parrott, 2002). MDMA can be 
especially dangerous if combined with other serotonergic drugs or 
medicines. Chronic or repeated MDMA can adversely affect the integrity 
of the serotonergic system. In laboratory animals, this leads to a pattern 
of selective changes to the distal serotonin axon terminals (Puerta, 
Hervias, & Aguirre, 2009); this is often termed ‘serotonergic 
neurotoxicity’, although there is debate over the exact nature of these 
serotonergic changes. Biezonski and Meyer (2011) noted that some 
explanatory models suggest distal axon terminal loss, while other 
models suggest neuroadaptive changes. Despite the different models, it 
was noted that the empirical evidence for MDMA-induced serotonergic 
depletion was overwhelming. Hence Biezonski and Meyer (2011) 
concluded that MDMA was certainly ‘neurotoxic’—in that it impaired 
the serotonergic system. Similar conclusions have been offered by 
Reneman, de Win, van den Brink, Booij, and den Heeten (2006), Puerta 
et al. (2009), Benningfield and Cowan (2013). The following articles 
should also be consulted (McCann et al., 2008; Kish et al., 2010; Erritizoe 
et al., 2011; Di Iorio et al., 2012; Yegting et al., 2016), where they also 
debate the complex issue of whether this damage is permanent. 
The hypothalamic-pituitary-adrenal (HPA) axis is crucial for homeostasis, 
the everyday maintenance of psychological balance, and physiological 
health. The master neurohormone for homeostatic control is cortisol, 
and this is strongly affected by acute and chronic MDMA. In placebo-
controlled laboratory trials, an acute dose of MDMA generates a cortisol 
increase of around 100–200% 1–3 hours later (Harris, Baggott, 
Mendelson, Mendelson, & Jones, 2002; Dumont & Verkes, 2006). When 
taken at dance clubs, the increase in cortisol can peak at around 800% 
of baseline values (Parrott, 2016). This dramatic cortisol increase was 
originally found in dance clubbers who had self-administered Ecstasy, 
with MDMA being biochemically confirmed (Parrott et al., 2008). No 
changes in cortisol were found when the same participants went dance 
clubbing off-MDMA (Figure 15.1). In a parallel house-party study, an 
almost identical peak cortisol increase of 800% again emerged (Parrott 
et al., 2007). These pronounced increases in cortisol were far greater 
than those found in most situations. For instance, the standard 
psychophysiological stress test of ‘cycling to exhaustion’, leads to a peak 
cortisol increase of around 80–140% (for relevant studies, see reviews 
by Parrott (2009, 2016). MDMA can also induce changes in other 
neurohormones, including oxytocin, testosterone, and prolactin (Figure 
15.1; review—Parrott, 2016). 
 Figure 15.1 Cortisol and Testosterone Levels of Recreational 
Ecstasy/MDMA Users Dance-Clubbing. Twelve unpaid volunteers were 
assessed on self-administered MDMA, and while abstaining from 
MDMA, over counterbalanced weekends at the same dance club venue, 
with the same group of friends. P-levels represent paired comparisons 
with the pre-drug baseline (after: Parrott et al., 2008) 
The repeated use of MDMA can also lead to enduring changes in cortisol 
reactivity (Gerra et al., 2003; Verkes et al., 2001). Baseline cortisol levels 
may be changed, and cortisol responses to stress altered (Gerra et al., 
2003). Wetherell and Montgomery (2014) found that the cortisol 
awakening response was significantly higher in drug-free 
Ecstasy/MDMA users on a high-stress day, with cortisol levels late at 
night also raised. Frokjaer et al. (2014) similarly found an increase in the 
cortisol awakening response with regular Ecstasy/MDMA users, while 
this enhanced cortisol response was associated with greater prefrontal 
binding of the serotonin transporter (see previous section on 
neurotoxicity). Parrott et al. (2014a) found 400% higher levels of cortisol 
in the hair of recent regular Ecstasy/MDMA users, while light/minimal 
recent users also showed a trend for higher cortisol levels. Hence there 
are various indications of altered stress reactivity, with MDMA-induced 
changes to both the neurotransmitter and neurohormonal systems. 
Acute and chronic MDMA can lead to a range of functional abreactions, 
with damage to many different aspects of physical and psychological 
health. The following sections will focus on these abreactions and their 
clinical management. 
Hyperthermia: Incidence, Dangers, and Medical Treatment 
MDMA can cause thermal stress and overheating. In the laboratory, 
Freedman et al. (2005) reported that acute MDMA generated a 
significant increase in core body temperature, with 2.0 mg/kg leading a 
mean peak increase of 0.7oC. In laboratory studies, these thermal 
increases are dose related, with higher doses leading to higher core 
body temperatures (see summary table 2 in Parrott, 2012). Most 
recreational Ecstasy/MDMA users report feeling hot, sweaty, or 
dehydrated (Davison & Parrott, 1997; Topp et al., 1999; Parrott et al., 
2008). One American dance clubber on MDMA noted that ‘it feels like 
your blood is 115 degrees Fahrenheit’ (Cohen, 1998). With Australian 
party goers, Morefield, Keane, Felgate, White, and Irvine (2009) found a 
group mean body temperature increase of +1.1oC and an average skin 
temperature increase of +1.8oC. In a similar UK study, the group mean 
peak increase was +1.2oC (Parrott & Young, 2015), although other 
studies found smaller increases (review: Parrott, 2012). Many dance 
clubbers visit the ‘chill-out’ room to rest and recover, although some 
continue to dance for prolonged periods (Suy, Gijsenbergh, & Baute, 
1999), or dance continuously with minimal breaks (Parrott et al., 2006). 
In some recreational MDMA users, the hyperthermia can be severe and 
may require medical intervention to prevent a fatal outcome. The first 
documented case study of successful medical intervention was outlined 
by Brown and Osterloh (1987). A young woman was admitted to 
hospital two hours after taking 100–150mg of MDMA powders. Her 
body temperature on admission was 41.6ºC, and this hyperthermia was 
soon reduced by ice packs. In the following days, rhabdomyolysis, 
coagulopathy, visual hallucinations, toxic hepatitis, and a herpes-like 
skin rash developed. Intensive care was successful and led eventually to 
her medical discharge. Chromatography revealed pure MDMA in the 
powders she had taken, and toxicological analysis revealed that no 
other drugs had been consumed. The friend who took her to hospital 
had taken the same MDMA powders, without a pronounced thermal 
reaction, while both women had taken MDMA previously. The first 
documented MDMA-hyperthermic fatality was described by Chadwick 
et al. (1991). A 16-year-old girl was admitted to hospital with an axillary 
temperature of 40ºC and a provisional diagnosis of amphetamine 
overdose. Two hours later, the axillary temperature had increased to 
42ºC, and with fresh oral bleeding, she was moved to the intensive care 
unit. Intubation and ventilation were accompanied by haemodynamic 
monitoring and multiple medical interventions, including 35 units of 
blood and 21 units of platelets. The patient died 36 hours after 
admission. Toxicological analysis revealed 0.424 mg/l MDMA on 
admission, with no other drugs. Police enquires revealed that she had 
taken a single tablet of Ecstasy—and that this was her second 
Ecstasy/MDMA experience. 
Further MDMA fatalities due to hyperthermia were described by Henry, 
Jeffries and Dawling (1992). The body temperatures on hospital 
admission ranged between 40–43ºC, and they displayed similar patterns 
of hyperthermic abreaction, including disseminated intravascular 
coagulation, rhabdomyolysis, and acute renal failure. The dosage levels 
varied considerably; the lowest plasma MDMA level was 0.11mg/l, while 
the highest was 1.26mg/l. In just one case, other psychoactive drugs 
were present, with low levels of amphetamine and MDA. Henry et al. 
(1992) also described four cases where initial body temperatures were 
around 40ºC, with intensive medical intervention being successful. Patel 
et al. (2005) described six case studies of MDMA-related hyperthermia, 
including three individuals who had been at the same rave party. The 
first was a 20-year-old woman who was found unresponsive at the 
party. Her skin felt ‘very hot’ to the touch, and intensive resuscitation 
was immediately attempted but was unsuccessful. Toxicological analysis 
revealed 1.21 mg/l MDMA and 0.40 mg/L methamphetamine. The 
second case was a 20-year-old male in a coma, with hot, dry skin and an 
oral temperature of 41.5ºC. Intensive medical intervention with rapid 
physical cooling in an ice bath reduced his temperature to 38.1ºC, and 
he was discharged. Urine toxicology revealed MDMA alone; subsequent 
discussions revealed that he had previously taken similar amounts of 
Ecstasy/MDMA without adverse reactions. A third emergency hospital 
admission needed physical restraint by the police. Cooling blankets, ice 
baths, and isotonic intravenous liquids reduced the high temperature of 
40.7ºC on admission. Laboratory analysis revealed that the Ecstasy pills 
contained pure MDMA. Many other cases of MDMA-induced 
hyperthermia have been described, often with successful medical 
intervention, although some resulted in fatalities (Corre, 1996;; Schifano 
et al., 2003, 2010; Grunau, Wiens, & Brubacher, 2010). 
The core treatment for MDMA-hyperthermia is rapid cooling (; Rusyniak 
and Sprague, 2005; Grunau et al., 2010). In a medical article, Hall and 
Henry (2006) described the different type of thermal abreaction caused 
by MDMA and outlined the treatment options for the accompanying 
hyperpyrexia and multi-organ failure. They noted that ‘Patients with 
acute MDMA toxicity may present to doctors working in Anaesthesia, 
Intensive Care and Emergency Medicine. A broad knowledge of these 
pathologies and their treatment is necessary for those working in an 
acute medicine speciality’. In an Israeli study, Halpern et al. (2011) 
summarized the medical profiles of MDMA-related emergency hospital 
admissions. Common manifestations included restlessness, agitation, 
disorientation, shaking, high blood pressure, headache, and loss of 
consciousness; while more serious cases involved severe hyperthermia 
(and hyponatraemia—see next section). The authors emphasized that in 
their experience, the widespread perception of Ecstasy as a safe party 
drug was ‘spurious’. Grunau et al. (2010) recommended the use of 
dantrolene in cases of severe (<40.0ºC) or extreme (<42.0ºC) 
hyperthermia. For more moderate hyperthermia, the standard 
approach was immediate cooling with air fans or ice baths. Greene et al. 
(2009) reviewed 332 MDMA-related admissions to the emergency 
department of one London Hospital over a three-year period. Core body 
temperatures on admission ranged from very low (34.1ºC) to very high 
(41.6ºC). The cases of low temperature reflect the core fact that MDMA 
impairs thermoregulation, so that in cold environments, the body cools 
excessively. Medical treatment in such cases is immediate warming 
(e.g., into a warm bed vacated by another patient!) 
Table 15.2 Overview of Chronic Problems Caused by Repeated 
Ecstasy/MDMA and Their Treatment 
Chronic 
Problem  
Occurrence  Management-
Treatment  
References 
Memory 
deficits 
In most 
regular users; 
stronger 
deficits in 
heavier users; 
enduring 
problems 
over time 
Stop taking MDMA. 
Develop practical skills 
such as note taking.  
Krystal, 
Price,, 
Opsahl, 
Ricaurte, & 
Heninger, 
1992 
Spatt, 
Glawar, & 
Mamoli, 
1997. 
Parrott, 
Lees, 
Garnham, 
Jones, & 
Wesnes, 
1998. 
Laws & 
Kokkalis, 
2007 
Wunderli et 
al., 2017. 
Prospective 
memory 
deficits 
Commonly 
reported, 
dosage-
related, more 
problems in 
heavier users 
Stop taking MDMA. 
Develop practical skills. 
Use diaries and/or 
electronic planners.  
Heffernan, 
Jarvis, 
Rodgers, 
Scholey, & 
Ling, 2001 
Rendell, 
Gray, 
Henry, & 
Tolan, 2007 
Montgomer
y, Hatton, 
Fisk, Ogden, 
& Jansari, 
2010 
Parrott, 
2013a,b 
Simple 
cognitive 
skills 
Not impaired  No treatment required.  Mc Cann et 
al., 199-98. 
Parrott et 
al., 1998 
Higher 
cognitive 
deficits and 
Found in 
moderate and 
heavier users.  
Some heavy users may 
need to move to 
simpler 
Fox et al., 
2001, 2002. 
reduced 
problem-
solving 
abilities 
occupations/employme
nts. Stop taking MDMA.  
Fisk, 
Montgomer
y, Wareing, 
& Murphy, 
2005. 
Taurah, 
Chandler, & 
Sanders, 
2013 
Parrott, 
2013b 
Brain 
changes 
(ERPs, fMRI, 
other 
indices) 
Mostly in 
moderate or 
heavy users; 
light users 
less impaired 
Many users 
compensate by putting 
more effort into task 
performance. Stop 
taking MDMA. 
Reneman et 
al., 2006. 
Kish et al., 
2010 
Burgess et 
al., 2011. 
Roberts, 
Quednow, 
Montgomer
y, & 
Parrott, 
2017 
Psychiatric 
problems: 
depression, 
anxiety, 
anger, 
aggression 
Mild to 
moderate 
distress in 
many regular 
users; more 
severe 
problems in 
some 
individuals 
Cessation of MDMA can 
reverse the psychiatric 
deficits.  
Schifano et 
al., 1998. 
Parrott et 
al., 2000, 
2001 
Verheyden 
et al., 2003 
Briere et 
al., 2012. 
Turner et 
al., 2014 
Sleep 
impairment 
Around 70% 
of 
recreational 
users  
Stop taking MDMA. 
Read more books at 
night? 
McCann & 
Ricaurte, 
2007 
Ogeil, 
Rajaratnam
, & 
Broadbear, 
2013 
Sleep 
apnoea 
Minority of 
regular users  
Stop taking MDMA. No 
known therapy. 
McCann, 
Sgambati, 
Schwartz, & 
Ricaurte, 
2009. 
Cortisol and 
HPA axis  
400% 
increase in 
hair cortisol 
samples, 
impaired 
homeostasis  
Many adverse 
implications of altered 
HPA axis. Stop taking 
MDMA. 
Gerra et al., 
2003. 
Parrott, 
2009, 2016 
Parrott et 
al., 2014a,b 
Dental 
problems 
Excessive 
chewing, 
worn down 
molars, hole 
in chewed 
skin below 
mouth.  
Stop taking MDMA. 
Dental restoration is 
limited; facial 
restoration is limited. 
Redfearn, 
Agrawal, & 
Mair, 1998 
Nugent, 
Basyuni, 
McAnerney
, & 
Cameron, 
2017 
Foetal 
abnormaliti
es  
Cardiovascula
r and 
musculoskele
tal anomolies  
Do not take MDMA 
without contraception. 
McEllhaton 
et al., 1999  
Neonates: 
delayed 
psychomot
or 
developme
nt 
Prospective 
study of 
women who 
took MDMA 
during 
pregnancy  
Females should not 
take MDMA during 
conception or 
pregnancy. Males 
should not take MDMA 
during conception. 
Singer, 
Moore, & 
Fulton, 
2012; 
Singer, 
Moore, & 
Min, 2012; 
Singer et 
al., 2015 
Another important question is whether chronic MDMA damages 
thermoregulatory ability. There is a paucity of empirical data on this 
question, although some indirect evidence. Parrott and Young (2015) 
measured body temperatures of dance clubbers and found raised 
temperatures in current MDMA users compared to never-user controls 
who were mostly alcohol drinkers. The third group comprised dancers 
who had not taken MDMA that weekend but who had taken it 
previously. Their body temperatures were significantly raised in 
comparison to the never-user controls, suggesting that the previous use 
of MDMDA had impaired their thermoregulatory abilities. In a recent 
British legal case, a soldier who had taken MDMA 3 days previously died 
of heatstroke when subjected to physical exercise on a hot day. The 
court case focused on the residual effects of acute MDMA. As an expert 
witness, I agreed that this was certainly important. However, I also 
noted that any impairment in thermoregulatory ability might also reflect 
the effects of chronic MDMA. Empirical research is required to test this 
hypothesis. Certainly, the armed forces may need a better 
understanding of this issue, given that hyperthermia (prolonged military 
exertions in hot countries) and hypothermia (fighting in arctic 
conditions, downed aircrew in cold sea emersions) are potentially lethal 
occupational hazards of military personnel. 
Hyponatraemia: Incidence Rates, Health Dangers, and Treatment 
When feeling hot and thirsty, many recreational MDMA users drink 
large amounts of water. This can lead to hyponatraemia, or the dilution 
of sodium electrolytes in the blood serum (Halpern et al., 2011; Baggott 
et al., 2016). The effects of excessive fluid intake may be compounded 
by changes in the anti-diuretic hormone, which reduces micturation 
(peeing) and further contributes to this electrolyte dilution. Hence 
hyponatraemia is a hazard for all recreational Ecstasy/MDMA users. At 
one Dutch rave, Van Dijken, Blom, Hene, and Boer (2013) took blood 
samples from volunteers in order to measure their plasma sodium 
levels. This revealed mild hyponatraemia (Na < 130 mmol/L) in 25% of 
the female MDMA subgroup, compared to 3% of the male subgroup. 
This gender difference was apparent despite similar rates of 
Ecstasy/MDMA consumption. Gender differences had also been noted 
in an earlier American study, where 17 of the 18 documented 
hyponatraemia cases were female (Budisavljevic, Stewart, Sahn, & 
Ploth, 2003). The California Poisons Unit reviewed 1,407 cases of 
MDMA-attributed hyponatraemia which were reported from 2000–
2005 (Rosenson et al., 2007). Full data was lacking in most cases, but 
where blood samples had been taken, clinically confirmed 
hyponatraemia was significantly more evident in females. Other 
amphetamine drugs were present in some cases, while females also 
displayed an increased risk of hyponatraemia-with-coma. Potential 
reasons for the gender imbalance were lower female body weight (viz: 
resulting in higher drug concentrations) and neurohormonal factors. 
Cortisol, oxytocin, and many other neurohormones are known to be 
affected by MDMA (Parrott, 2006; see earlier section), and gender may 
be a co-factor. The menstrual cycle affects psychobiological reactions to 
nicotine (Craig et al., 1993) and may influence responses to many other 
drugs including MDMA. 
For optimal clinical management, blood electrolyte levels should be 
assessed on admission and sodium levels restored immediately (Hall & 
Henry, 2006; Halpern et al., 2011). Rapid intervention can be very 
successful, although hyponatraemia may prove lethal if not reversed in 
time. Many cases are brought to the attention of the emergency 
medical services too late, with resulting fatalities. Schifano et al. (2010) 
analyzed the government data on recreational stimulant deaths in the 
UK between 1997 and 2007. Over this period, there were 832 deaths 
related to amphetamine or methamphetamine and 605 related to 
Ecstasy/MDMA. Many were related to multiple drug ingestion or 
‘polydrug’ use. However, in the analysis of ‘mono-intoxication’ fatalities, 
Schifano et al. (2010) found that deaths following Ecstasy/MDMA alone 
were significantly overrepresented in comparison with deaths following 
amphetamine or methamphetamine alone (when considered in relation 
to overall usage rates). There are also indications of increasing death 
rates recently. For instance, on the ‘party island’ of Ibiza, acute deaths 
due to Ecstasy/MDMA and cocaine increased significantly from 2010 to 
2015 (Santacroce et al., 2017). 
Causes of Death: Medical Treatments and Prevention Strategies 
Hall and Henry (2006) reviewed the medical scenarios and treatment 
options for physicians working in emergency medicine. They noted that  
Hyperpyrexia and multi-organ failure are now relatively well-known, 
other serious effects have become apparent more recently. Patients 
with acute MDMA toxicity may present to doctors working in 
Anaesthesia, Intensive Care and Emergency Medicine. A broad 
knowledge of these pathologies and their treatment is necessary for 
those working in an acute medicine speciality. 
 They noted that MDMA can cause death by various forms of organ 
failure. In laboratory studies with animal liver tissue, MDMA can induce 
apoptosis or programmed cell death (see reviews Parrott, 2013a, 
2013b), with some recreational users suffering from fatal liver failure. 
Smith et al. (2005) described case studies of young people whose livers 
had been damaged by acute MDMA, with some then requiring 
emergency liver transplantation. Other fatalities result from cardiac 
arrest, brain seizure, and rhabdomyolysis or the destruction of skeletal 
muscle tissue. Some of the previous case studies in this chapter have 
summarized the emergency medical interventions, both successful and 
unsuccessful. One frequently lethal outcome is disseminated 
intravascular coagulation or DIC, where the failure of blood clotting 
leads to uncontrollable bleeding though multiple sites (Henry et al., 
1992; Hall & Henry, 2006). 
Tolerance, Dependency, and Therapeutic Potential 
Shulgin (1986) suggested that ‘MDMA does not lend itself to overuse 
because its most desirable effects diminish with frequency of use’. 
Many other early reports suggested that MDMA was unique in this 
aspect, further noting that tolerance reduced its abuse liability. In an 
interview study with early American MDMA users, Peroutka, Newman, 
and Harris (1988) noted that its positive effects were said to decline 
with repeated usage, as its adverse effects increased. In a UK study from 
1992–3, recreational users reported that they took MDMA-free breaks 
of several weeks in order to minimize ‘drug habituation’ (Davison & 
Parrott, 1997). However, many regular users just increase their dosing. 
Fox et al. (2001) found that the maximum single session dosage 
increased from 3.6 tablets in light users to 5.5 tablets in moderate users 
and 10.9 in heavy users. For more studies on dosage escalation, see the 
review by Parrott (2005). Hammersley, Ditton, Smith, and Short (1999) 
reported that MDMA bingeing was noted by 76% of heavier users, 
compared to 16% of light users. This more intensive Ecstasy/MDMA 
usage led to more days-off work because of illness, reduced appetite, 
and more episodes of depression. Some patterns of bingeing were quite 
extreme, with repeated MDMA self-dosing for 48 hours or more 
without sleep (Topp et al., 1999). Some very experienced users inject 
MDMA (Topp et al., 1999; Downey et al. (2017)), although the hit can be 
‘too intense to enjoy’ and the post-drug comedown even worse than 
usual. 
Every CNS stimulant drug has addiction potential, although MDMA has a 
comparatively low potential—for two reasons. The most addictive 
stimulant drugs have a rapid hit—followed by a rapid comedown; hence 
the highest addiction potentials are displayed by crack cocaine and ice 
methamphetamine (Parrott, 2015). In contrast, the initial effects of oral 
MDMA develop slowly and are followed by a long-lasting comedown 
period of several days (Parrott & Lasky, 1998). Hence MDMA tends to be 
used infrequently, most typically less than once a week (Parrott, 2005). 
Secondly, MDMA damages the serotonin system (Kish et al., 2010; 
Benningfield & Cowan, 2013), and this reduces its efficacy over time. 
Hence regular users take the drug less frequently than novice users, 
before ceasing usage (review: Parrott, 2005). Because of this low 
addiction potential, drug addiction centres are rarely attended by 
individuals seeking help for MDMA dependency. This leads some 
addiction experts to believe that MDMA is not a problematic drug. This 
belief is mistaken, since while MDMA displays low addiction potential, it 
does cause a wide range of other neuropsychobiological problems, as 
listed in Table 15.2 (Topp et al., 1999; Parrott, 2000, 2001, 2006, 
2013a.b). 
MDMA has been assessed as a drug-adjunct for psychotherapy, and 
most reports in this field have focused on its potential benefits 
(Mithoefer, Bateman, Evans, Pughe, & Thomas, 2016; Wagner et al., 
2017). However, there are many potential dangers from using this 
powerful CNS stimulant drug, and even in the restful therapeutic 
environment, clinical casualties have been reported (Greer & Tolbert, 
1986; Parrott, 2007, 2014, 2018). The first detailed report of MDMA-
assisted therapy was by Greer and Tolbert (1986), and they noted that 
all 29 clients reported some positive gains, but every client also 
reported some negative experiences. In relation to overall balance, 
while some clients reported overall benefits from MDMA, others had 
more negative overall experiences. In particular, some individuals with 
pre-existing psychiatric problems experienced a reoccurrence of 
symptoms. This led Greer and Tolbert (1986) to conclude ‘There is an 
indication that MDMA may predispose people to a recurrence of 
previous psychological disabilities’. Another potential problem is dosage 
escalation. One of their clients did not respond positively to the normal 
dose, so he or she was given a higher dose of MDMA. This generated a 
severe abreaction, with side effects which included ‘nausea, small 
amount of vomiting, jaw tension, ataxia, urinary urgency, blurred vision, 
sweating, brief short-term memory loss, brief distortion of depth 
perception with a brief hallucination’. Despite this severe abreaction, 
dosage escalation in non-responsive clients has also occurred more 
recently (see Parrott, 2018). Further information on the potential 
problems of MDMA-assisted psychotherapy are contained in the 
following reviews (Parrott, 2007, 2014, 2018). 
Psychiatric Disturbances 
MDMA has acute and chronic effects on the serotonin system and the 
HPA axis. Hence it is not surprising that it can exacerbate various 
psychiatric conditions (Cowan & Lucki, 2011; Parrott, 2013a, 2013b; 
Parrott & Lasky, 1998; Parrott et al., 2000, 2001, 2014a,b). Schifano et 
al. (1998) found that regular MDMA users reported various 
psychopathological problems, including depression, psychotic disorders, 
feelings of panic, problems with impulse control, and eating disorders. 
MacInnes, Handley, and Harding (2001) found significantly higher 
depression scores in Ecstasy/MDMA users than non-user controls, 
despite all participants being screened for previous psychiatric distress. 
In a statistical review, Rogers et al. (2009) found that problems with 
depression, impulsivity, and anxiety were significantly worse for 
Ecstasy/MDMA users than for polydrug controls. Briere et al. (2012) 
prospectively monitored 3,880 disadvantaged schoolchildren in Canada; 
those children who started taking MDMA reported significantly higher 
depression one year later. Scholey et al. (2010) found that abstinent 
Ecstasy/MDMA users reported feeling significantly more stressed than 
non-user controls. Wetherell et al. (2012) reported that abstinent users 
were significantly less calm when performing a stress-induction task. 
Reid, Elifson, and Sterk (2007) found increased hostility and aggression 
in heavier Ecstasy/MDMA lifetime users and questioned whether 
MDMA was best described as a ‘hug drug’ or as a ‘thug drug’. Gerra et 
al. (2001) found that the heavier lifetime Ecstasy/MDMA users showed 
more aggressive reactions to a standard behavioural aggression task. In 
a large American population survey, Vaughn, Salas-Wright, DeLisi, 
Perron, and Cordova (2015) found that MDMA users were involved in 
more crimes of violence and crimes of non-violence than non-users. This 
was found in both genders, with female MDMA users being more 
antisocial than male non-users. Rugani et al. (2012) studied clinical cases 
of acute psychosis at an Italian psychiatric hospital. Those who had 
taken Ecstasy/MDMA reported significantly higher levels of hostility, 
physical violence, and verbal aggression. This led to the following 
conclusion: ‘Psychosis with a high level of aggressiveness and violence 
constitutes an important “side-effect” that surely runs counter to the 
expected entactogenic actions of Ecstasy’. 
In relation to therapy, I am not aware of any study that has specifically 
investigated MDMA users. Hence psychiatrists are advised to follow the 
normal therapeutic procedures, for each form of psychiatric condition. 
One crucial piece of advice is to stop taking MDMA, since it is well 
established that the incidence of problems increases with greater 
lifetime usage (Kish et al., 2010; Parrott, 2013a, 2013b). Yet in order for 
this practice to become usual, psychiatrists and physicians need to be 
educated about its adverse effects. Mental health improves after 
cessation of other recreational stimulants, such as amphetamines or 
cocaine, and similar gains have been found following Ecstasy/MDMA 
cessation (Parrott, 2015; Parrott, Hayley et al., 2017). Morgan, McFie, 
Fleetwood, and Robinson (2002) found that current and former MDMA 
users displayed heightened psychopathology scores, while former users 
were less impaired. Verheyden, Maidment, and Curran (2003) also 
found that 70% of former Ecstasy users reported ‘improved mental 
health’ after quitting the drug. In a two-year prospective study, Turner 
et al. (2014) found that young mothers who quit using MDMA reported 
significantly reduced depression rates 18 months later. Indeed their 
heightened Brief Symptom Inventory depression scores as MDMA users 
returned to control group values following cessation. However, not all 
studies report psychiatric gains, with Taurah et al. (2013) finding that 
depression scores remained significantly raised in former MDMA users. 
Neurocognitive Deficits 
The first chronic deficits to be empirically described in recreational 
Ecstasy/MDMA users were problems with memory (McCann and 
Ricaurte, 1991; Krystal et al., 1992). Performance deficits on standard 
cognitive tests of memory were subsequently confirmed in the first 
cohort studies, with impairments in immediate and delayed word recall 
(Parrott et al., 1998) and impaired prose recall (Morgan, 1999). An early 
review of 20 published studies found deficits with many different 
memory tasks (Parrott, 2001). A later meta-analysis reported moderate 
to large ‘effect sizes’ for different types of memory deficit, including 
short-term and long-term verbal memory (Laws & Kokkalis, 2007). 
Another comprehensive review noted that the retrospective memory 
deficits of abstinent Ecstasy users were significant in comparison with 
both non-user controls and polydrug user controls (Rogers et al., 2009). 
The complex mixture of deficits on some cognitive tasks and normal 
performance with other cognitive functions has been noted in many 
papers and reviews (McCann et al., 1999; Parrott, 2001, 2006, 2013a, 
2013b; Burgess et al., 2011; Rogers et al., 2009; McCann & Ricaurte, 
2014; Roberts et al., 2017). Many of the neurocognitive and related 
problems of MDMA users are also similar in some ways to those caused 
by other recreational drugs, such as amphetamine or cocaine (Table 
15.3; Parrott et al., 2011). So that while retrospective memory deficits 
are found in ‘relatively pure’ MDMA users, the memory problems may 
be worsened by additional drug usage (Mohamed et al., 2011; Wunderli 
et al., 2017). 
Another key type of memory is prospective memory, for instance, 
remembering to meet someone at a prearranged time and place—in the 
future. This more complex aspect of memory involves cognitive and 
temporal planning and seems even more sensitive to the damaging 
effects of recreational Ecstasy/MDMA (Parrott, 2013a,b). The first 
report of prospective memory deficits (Hefferman et al., 2001) has been 
confirmed using a wide variety of task paradigms (review: Parrott, 
2013b). The extent of these deficits increases with greater lifetime 
usage (Rendell et al., 2007), and many recreational Ecstasy/MDMA 
users report problems with their prospective memory ability (Rodgers et 
al., 2003). One study employed a virtual reality task that modelled the 
multiple daily tasks of an office worker; the significant deficits of the 
Ecstasy users were attributed to problems in memory and task 
organization (Montgomery et al., 2010). Simple problem-solving skills 
are also impaired in drug-free MDMA users (review: Parrott, 2013b). Fox 
et al. (2001) found that performance on a problem-solving task was 
250% slower in heavy users, with light and moderate users being 
cognitively impaired to lesser extents. With the Cambridge 
Neurocognitive Test Battery (CANTAB), the cognitive profiles of drug-
free Ecstasy/MDMA users were found to be similar to those of clinical 
patients with brain damage to the temporal lobes (Fox et al., 2002). 
Deficits have been found in a wide range of higher cognitive tasks, and 
they are accompanied by significant reductions in social intelligence 
(Reay, Hamilton, Kennedy, & Scholey, 2006). 
In relation to neurocognitive therapy, Spatt et al. (1997) described a 
‘pure amnesic syndrome’ in a 26-year-old female who had taken 
Ecstasy/MDMA at a rave with adverse consequences. Three days 
afterward, her performance on standard memory tests was below the 
fifth percentile, while an MRI scan revealed ‘bilateral hyperintense 
lesions in the globus pallidus’. Occupational therapy as an outpatient 
was provided for several months, but this was not able to improve her 
memory problems, and nine months later, her objective memory task 
performance remained impaired. On the positive side, she ‘learned to 
make extensive use of a diary and a timetable’, although she had not 
been able to return to her previous employment. This degree of 
memory impairment may be extreme, but many users note that their 
neurocognitive skills are impaired (Fox et al., 2001, 2002; Parrott, 2000). 
These cognitive impairments are often accompanied by deficits in other 
skills, such as visual information processing and psychomotor ability. 
These diverse impairments can have adverse implications for many daily 
activities and professional occupations; for an overview and debate, see 
the final section in Parrott (2013b). 
Many drug problems are resolved by abstinence, which leads to the 
question of whether quitting Ecstasy/MDMA will restore normal 
cognitive functioning. While some degree of functional recovery might 
be expected, the empirical evidence on this question is not hopeful. 
Morgan et al. (2002) found that the Rivermead paragraph memory test 
scores of former Ecstasy/MDMA users, who had quit for a mean of two 
years, were around 50% of the scores of never-user controls. Zakzanis 
and Campbell (2006) found mixed evidence, with some indications of 
recovery and other indications of enduring memory deficits. Taurah et 
al. (2013) found that general memory, verbal memory, visual memory, 
and delayed memory were all significantly impaired in current MDMA 
users compared to polydrug controls and that former MDMA users 
displayed enduring deficits on these same tasks. Crucially they found no 
indications of cognitive skills being restored, despite an average of four 
to five years of abstinence. Soar, Parrott, and Turner (2004) described a 
case study of severe cognitive deficits seven years after quitting. 
Table 15.3 Neurocognitive Performance and Self-Rated Moods in 
Recreational Cocaine and Ecstasy/MDMA Users: Comparative Effects 
from Three Co-Studies (after: Parrott et al., 2011). 
Study 1: L. Evans. 
Memory and 
Cognition 
Control Group Cocaine/MDMA  MDMA  
Dysexecutive 
Questionnaire 
(problem score) 
22.1 38.2*** 37.1** 
Consonant updating 
(correct recall) 
 3.2  3.1  2.1 
Random letter 
(number generated—
two/seconds) 
98.1 83.1*** 96.6 
Supraspan word recall 
(total words) 
31.1 29.9 27.9 
    
Study 2: J. Howell. 
Mood States On-Drug 
and Post-Drug 
Recovery 
Control/Alcohol  Cocaine  MDMA  
Excitement (on-drug) 3.6 4.0 4.7* 
Paranoia (on-drug) 1.5 3.0* 2.5 
Clearheaded (on-drug) 3.0 3.1 1.8* 
Aggression (on-drug) 2.3 3.1 1.5 
Over-heated (on-drug) 2.5 3.5* 3.9** 
    
Depressed (post-drug 
recovery) 
2.1’ 2.7 3.2* 
Paranoia (post-drug 
recovery) 
1.6 2.6* 3.6*** 
Sociable (post-drug 
recovery) 
3.7 3.1 2.3** 
Clearheaded (post-
drug recovery) 
3.8 3.3 2.1** 
    
Study 3: R. Robart. 
Memory and 
Cognition 
Control Group Cocaine  MDMA  
Rivermead 
Behavioural Memory 
(info recalled) 
9.9 9.2 8.9 
Auditory Verbal 
Learning task (words 
learned) 
9.4 8.0 7.2* 
Trail Making (task 
completion time) 
15.9 19.9 21.4** 
Tukey paired comparison tests with control group (two-tailed): 
* p < 0.05 **p < 0.01 *** p < 0.001 
Sleep 
MDMA can alter sleep patterns, both acutely and chronically. Jones, 
Callan, Blagrove, and Parrott (2008) described the patterns of self-
reported sleep after weekend Ecstasy/MDMA. They noted significant 
reductions in sleep time and sleep quality for several days afterward, 
with sleep patterns returning to normal after five or six days. In relation 
to chronic sleep effects in abstinent users, Allen, McCann, and Ricaurte 
(1993) found a reduction in total sleep time, due mainly to less stage 2 
non-REM sleep. In a review, McCann and Ricaurte (2007) concluded that 
abstinent Ecstasy/MDMA users were at increased risk for chronic sleep 
disturbances. In a later study, McCann et al. (2009) revealed the medical 
disorder ‘sleep apnoea’ in young recreational users, with incidence rates 
related to lifetime MDMA usage. The authors noted that serotonin was 
important in the control of breathing and hypothesized that this 
particular sleep disorder might be another reflection of serotonergic 
neurotoxicity. Ogeil et al. (2013) noted that around 70% of 
Ecstasy/MDMA users reported sleep disturbances. In relation to 
therapy, it is recommended not to administer sleep medications, since 
they all tend to be problematic when used chronically, because of 
tolerance or withdrawal problems. The best advice is abstinence—in the 
hope that sleep may gradually improve, although the limited evidence 
suggests that this disorder can be enduring (Taurah et al., 2013) and 
may possibly be permanent. 
Dental Problems 
In the first empirical investigation of recreational MDMA users at a 
Californian university, Peroutka et al. (1988) reported that the main 
psychophysiological effects of a typical dose of 125mg MDMA were 
tachycardia or increased heart rate, trismus or jaw clenching, and 
bruxism or tooth grinding. Most recreational users see these feelings of 
tight jaw, clenched teeth, grinding of the molars, and compulsive 
chewing as normal hazards. Indeed, some users take these 
physiological-psychomotor effects, along with other aspects of the 
serotonin syndrome, as indications that they have been sold genuine 
MDMA (Parrott, 2002). Tooth grinding and compulsive chewing can, 
however, cause dental problems. Nugent et al. (2017) described the 
case of an 18-year-old female, who presented for emergency medical 
treatment with extensive tissue loss to her lower lip. An accompanying 
friend reported that following MDMA, the patient demonstrated 
‘involuntary chewing of her lower lip. Despite the pain, this persisted for 
several hours’. This chewing caused a 3 cm loss of tissue in the lower lip 
and the tissue below it. Facial surgery attempted to join the remaining 
skin and jaw tissues together, although ‘no oral seal was achievable’; 
the photograph in the dental journal shows the remaining hole beneath 
the mouth and surrounding lip disfigurement. Kalant (2001) noted that 
bruxism was generally limited to the period of acute drug action, 
although in some MDMA users, the compulsive chewing and grinding 
persisted afterward. Chronic dental problems are thus a practical hazard 
for some MDMA users, with worn-down back molars being the main 
problem (Redfearn et al., 1998). 
Neonatal Problems 
Many psychoactive drugs can damage foetal development, and MDMA 
is no exception. McElhatton, Bateman, Evans, Pughe, and Thomas 
(1999) found that mothers who had used MDMA during pregnancy had 
children with an increased rate of congenital defects. These anomalies 
predominantly occurred in the cardiovascular and musculoskeletal 
systems. In a prospective investigation, the Drugs and Infancy Study 
(DAISY) monitored 28 mothers who took Ecstasy/MDMA during the first 
trimester of pregnancy (Moore et al., 2010). The control group 
comprised 68 mothers who had used other recreational drugs, legal 
and/or illicit, during their pregnancy and included several with 
Ecstasy/MDMA experience. The neonates and new mothers were 
prospectively assessed on a battery of psychological tests on several 
occasions. One heavily MDMA-exposed mother gave birth to a neonate 
with some congenital defects, a problem not found in the other groups. 
With the group comparisons, the more heavily MDMA-exposed 
neonates had significantly lower ‘motor quality’ scores at four months 
post-partum (Singer, Moore, Fulton et al., 2012), and these 
psychomotor deficits remained significant at the 12- and 24-month 
post-partum sessions (Singer, Moore, Min et al., 2012; Singer et al., 
2015). These findings need to be replicated, and the effects of MDMA 
on male sperm need to be studied. In relation to practical advice, all 
women should be advised to be drug-free for one month before 
planning a pregnancy. This advice should also be given to all men. 
 
Final Overview 
The use of MDMA leads to a wide range of acute and chronic problems 
(Tables 15.1 and 15.2). Furthermore, it has taken years of painstaking 
empirical research to reveal the multitude of these psychobiological 
deficits (Parrott, 2013a, 2013b). This has worrying implications for the 
many novel psychoactive substances now becoming available to illicit 
drug users (UNODC, 2018). Many of these new drugs will be damaging 
in ways both similar to, and dissimilar from, the more established drugs, 
such as cocaine, methamphetamine, or MDMA (Parrott, 2015). So that 
while some of the NPS-induced problems may be predictable, others 
may be more esoteric and difficult to understand. This makes it 
increasingly difficult for the physicians working in emergency medical 
centres. In relation to therapy, currently the empirical evidence for 
MDMA is very limited. The only area with good practical advice is the 
treatment of acute medical problems. Physicians and medics in hospital 
emergency departments have developed standard procedures for 
reversing acute hyperthermia by rapid cooling and reversing acute 
hyponatraemia by the immediate restoration of normal sodium levels 
(Table 15.1). Both disorders can be fatal when not treated rapidly, 
hence many thousands of lives have been saved by hospital physicians 
and medical staff. Other current medical treatments include liver 
transplantation following acute liver failure and blood transfusions with 
platelets for uncontrollable bleeding. 
Yet acute deaths from MDMA are currently increasing because of three 
main factors: higher dosage levels, the failure to bring casualties into 
hospital soon enough, and the increasing use of NPS co-drugs with 
unknown pharmacodynamics. 
The regular use of MDMA can lead to a range of chronic problems, 
caused by repetitive damage to the neurohormonal and 
neurotransmitter systems (Table 15.2). Currently, there is minimal 
knowledge about any effective therapies. Indeed, current limited 
knowledge suggests that much of the chronic damage caused by MDMA 
may be enduring (Taurah et al., 2013). Chronic deficits occur in a wide 
range of psychobiological functions: memory, problem-solving ability, 
some visual skills, psychomotor integrity, sleep, homeostasis, 
immunocompetence, and other areas (Parrott, 2013b). Severe 
consequences can occur after a single MDMA dose (Spatt et al., 1997) or 
following chronic repeated doses (Jansen, 1999; Soar et al., 2004). The 
typical user displays a moderate degree of impairment but one that is 
not disabling. For instance, 70% of MDMA users report sleep 
impairments—yet they can still sleep. Memory problems are reported 
by most regular users (Parrott et al., 2006), yet basic memory functions 
are retained (Fox et al., 2002; Kish et al., 2010). Problem-solving ability 
and social intelligence are reduced but are not completely lost (Reay et 
al., 2006). For many of these functions, heavy users are more impaired 
than light users (Fox et al., 2001; Rendell et al., 2007). 
Hence an important piece of practical advice for light users is to stop 
taking any more—in order to minimize the further development of any 
structural brain damage or functional deficits (Parrott, 2015). The 
various psychiatric problems caused by MDMA, such as depression, 
often seem to be reversed by abstinence (Turner et al., 2014). However 
current evidence suggests that neurocognitive functions may remain 
impaired over time (Taurah et al., 2014). Hence therapies should teach 
new life skills, such as note taking to cope with memory impairments, 
and social skills retraining to reverse the decline in social intelligence. In 
severe instances, retraining for simpler occupations or employments 
may be necessary (Spatt et al., 1997). In a debate of the potential 
implications of all these functional deficits, it was suggested that many 
everyday skills and occupational abilities could be impaired by regular 
MDMA usage (Parrott, 2013a, b). Hence the best practical advice is to 
reduce its usage entirely. In particular, we need to reverse the very 
misleading message that MDMA is safe for human consumption. 
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